Kezar Life Sciences Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
58
- Stock Symbol
-
KZR
- Share Price
-
$0.56
- (As of Friday Closing)
Kezar Life Sciences General Information
Description
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
Contact Information
Website
www.kezarlifesciences.comCorporate Office
- 4000 Shoreline Court
- Suite 300
- South San Francisco, CA 94080
- United States
Corporate Office
- 4000 Shoreline Court
- Suite 300
- South San Francisco, CA 94080
- United States
Kezar Life Sciences Timeline
Kezar Life Sciences Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.56 | $0.58 | $0.54 - $1.33 | $40.6M | 73M | 545K | -$1.35 |
Kezar Life Sciences Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | (117,831) | (129,781) | 204,315 | 773,406 |
| Revenue | 7,000 | 7,000 | 0 | 0 |
| EBITDA | (106,131) | (110,358) | (70,139) | (53,149) |
| Net Income | (98,568) | (101,870) | (68,239) | (54,630) |
| Total Assets | 179,921 | 221,235 | 299,568 | 217,933 |
| Total Debt | 17,610 | 18,933 | 21,264 | 14,044 |
Kezar Life Sciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Kezar Life Sciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Kezar Life Sciences Comparisons
Industry
Financing
Details
000000
000000
Kezar Life Sciences Competitors (59)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Arvinas | Formerly VC-backed | New Haven, CT | 000 | 00000 | 000000000 | 00000 |
| Affimed | Formerly VC-backed | Heidelberg, Germany | 00 | 00000 | 00000000 | 00000 |
| Black Diamond Therapeutics | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 00000000 | 00000 |
| Alector | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 000000 - 000 | 00000 |
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | 000 | 000.00 | 00000000 | 000.00 |
Kezar Life Sciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Kezar Life Sciences Patents
Kezar Life Sciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2023539553-A | Protein secretion inhibitor | Pending | 31-Aug-2020 | 0000000000 | |
| US-20230286973-A1 | Protein secretion inhibitors | Pending | 31-Aug-2020 | 0000000000 | |
| EP-4204417-A1 | Protein secretion inhibitors | Pending | 31-Aug-2020 | 0000000000 | |
| CA-3190441-A1 | Protein secretion inhibitors | Pending | 31-Aug-2020 | 0000000000 | |
| AU-2021334388-A1 | Protein secretion inhibitors | Pending | 31-Aug-2020 | C07D417/14 |
Kezar Life Sciences Executive Team (10)
| Name | Title | Board Seat |
|---|---|---|
| Christopher Kirk Ph.D | Co-Founder & Board Member | |
| Marc Belsky | Chief Financial Officer, Finance & Secretary, Administration | |
| Nick Mordwinkin | Chief Business Officer | |
| Jack Taunton Ph.D | Co-Founder |
Kezar Life Sciences Board Members (10)
| Name | Representing | Role | Since |
|---|---|---|---|
| Elizabeth Garner | Self | Board Member | 000 0000 |
| Franklin Berger | Self | Board Member | 000 0000 |
| Graham Cooper | Self | Chairman & Board Member | 000 0000 |
| John Fowler | Self | Founder & Board Member | 000 0000 |
| Michael Kauffman MD | Self | Board Member | 000 0000 |
Kezar Life Sciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Kezar Life Sciences ESG
Risk Overview
Risk Rating
Updated April, 01, 2023
25.27 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 16,009
Rank
Percentile
Pharmaceuticals
Industry
00 of 909
Rank
Percentile
Biotechnology
Subindustry
00 of 404
Rank
Percentile
Kezar Life Sciences FAQs
-
When was Kezar Life Sciences founded?
Kezar Life Sciences was founded in 2015.
-
Who is the founder of Kezar Life Sciences?
Christopher Kirk Ph.D and Jack Taunton Ph.D are the founders of Kezar Life Sciences.
-
Who is the CEO of Kezar Life Sciences?
Christopher Kirk Ph.D is the CEO of Kezar Life Sciences.
-
Where is Kezar Life Sciences headquartered?
Kezar Life Sciences is headquartered in South San Francisco, CA.
-
What is the size of Kezar Life Sciences?
Kezar Life Sciences has 58 total employees.
-
What industry is Kezar Life Sciences in?
Kezar Life Sciences’s primary industry is Drug Discovery.
-
Is Kezar Life Sciences a private or public company?
Kezar Life Sciences is a Public company.
-
What is Kezar Life Sciences’s stock symbol?
The ticker symbol for Kezar Life Sciences is KZR.
-
What is the current stock price of Kezar Life Sciences?
As of 06-Sep-2024 the stock price of Kezar Life Sciences is $0.56.
-
What is the current market cap of Kezar Life Sciences?
The current market capitalization of Kezar Life Sciences is $40.6M.
-
What is Kezar Life Sciences’s current revenue?
The trailing twelve month revenue for Kezar Life Sciences is $7M.
-
Who are Kezar Life Sciences’s competitors?
Arvinas, Affimed, Black Diamond Therapeutics, Alector, and Inovio Pharmaceuticals are some of the 59 competitors of Kezar Life Sciences.
-
What is Kezar Life Sciences’s annual earnings per share (EPS)?
Kezar Life Sciences’s EPS for 12 months was -$1.35.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
